Press Releases

BETHESDA, MD – August 3, 2010 – Northwest Biotherapeutics, Inc. (“NWBT” or the “Company”) (OTCBB: NWBO) today announced further positive long-term follow-up data from its prior Phase I and Phase I/II clinical trials, in which patients with newly diagnosed Glioblastoma multiforme (“GBM”), the most rapid and lethal type of brain cancer, were treated with NWBT’s DCVax®-Brain personalized immune therapy. The data through July 1, 2010, show that... Read More

BETHESDA, MD – July 7, 2010 – Northwest Biotherapeutics, Inc. (“NWBT” or the “Company”) (OTCBB: NWBO), developer of the DCVax® personalized cancer vaccines, announced today that during the second quarter it raised funding of $2.65 million from investors. The funding included $1.75 million in purchases of restricted common stock of the Company (the “Common Stock”) by a number of private investors, together with purchases of restricted Common... Read More

Comprehensive report by recognized Pharma and Biotech Analyst Dr. Navid Malik cites “striking data on survival” and “batch manufacturing at low cost” as key elements in DCVax’s “competitive advantage” in the “personalized cancer vaccine revolution.” BETHESDA, MD, June 7, 2010 – Northwest Biotherapeutics, Inc. (“NWBT”) (OTCBB: NWBO), developer of the DCVax® personalized cancer vaccine, today announced the release of a new detailed... Read More